Is Fulgent Genetics (flgt) stock a strong Buy Right Now?
· Fulgent Genetics stock has regained a bit of ground early in February's trading. The company's share price is up roughly 1% in the month so …
Is Fulgent stock headed for a big valuation pullback?
· Fulgent stock is incredibly cheap right now at just 6.5 times earnings. Its enterprise value is also far lower (the lower, the better) …
How much is a share of Fulgent worth?
· 29.50% of the stock of Fulgent Genetics is held by insiders. A high percentage of insider ownership can be a sign of company health. Percentage Held by Institutions. Only 37.61% of the stock of Fulgent Genetics is held by institutions. Previous Next
How did Fulgent's Revenue perform in Q1 2022?
This Stock Grew 135% Last Year and Is Down 50% From Its Highs Over the past couple of years, COVID-19 has led to some strong results for certain companies while others have faltered as a …
Is fulgent Genetics stock a buy?
Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy.
Who owns fulgent genetics?
Ming HsiehMing Hsieh is the founder, president, CEO and chair of Fulgent Genetics, a genetic testing technology company. He started Fulgent Genetics in 2011 and took the company public in 2016.
How much cash does fulgent genetics have?
Compare FLGT With Other StocksFullgent Genetics Annual Cash on Hand (Millions of US $)2020$2992019$282018$312017$263 more rows
What sector is fulgent genetics in?
Medical and Diagnostic Laboratories IndustryCompany Description: Fulgent Genetics, Inc. is located in Temple City, CA, United States and is part of the Medical and Diagnostic Laboratories Industry.
Is Fulgent Genetics a buy right now?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 sell rat...
How has Fulgent Genetics' stock price been impacted by Coronavirus?
Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organizati...
When is Fulgent Genetics' next earnings date?
Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Thursday, May 5th 2022. View our earnings forecast for Fulgen...
How were Fulgent Genetics' earnings last quarter?
Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings results on Wednesday, February, 23rd. The company reported $3.48 earnings per sh...
What guidance has Fulgent Genetics issued on next quarter's earnings?
Fulgent Genetics updated its FY 2022 earnings guidance on Wednesday, March, 16th. The company provided earnings per share guidance of $7.000-$7.000...
What price target have analysts set for FLGT?
2 brokerages have issued twelve-month price objectives for Fulgent Genetics' shares. Their forecasts range from $65.00 to $125.00. On average, they...
Who are Fulgent Genetics' key executives?
Fulgent Genetics' management team includes the following people: Ming Hsieh , Chairman, President & Chief Executive Officer James Xie , Chief Op...
Who are some of Fulgent Genetics' key competitors?
Some companies that are related to Fulgent Genetics include Guardant Health (GH) , Natera (NTRA) , Elekta AB (publ) (EKTAY) , Veracyte (VCYT) ,...
What other stocks do shareholders of Fulgent Genetics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA) , CR...
Is Fulgent Genetics a buy right now?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Fulgent Genetics stock.
What stocks does MarketBeat like better than Fulgent Genetics?
Wall Street analysts have given Fulgent Genetics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fulgent Genetics wasn't one of them.
Are investors shorting Fulgent Genetics?
Fulgent Genetics saw a drop in short interest in August. As of August 13th, there was short interest totaling 3,850,000 shares, a drop of 14.3% from the July 29th total of 4,490,000 shares. Based on an average daily trading volume, of 754,000 shares, the days-to-cover ratio is presently 5.1 days.
When is Fulgent Genetics' next earnings date?
Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.#N#View our earnings forecast for Fulgent Genetics.
How were Fulgent Genetics' earnings last quarter?
Fulgent Genetics, Inc. (NASDAQ:FLGT) announced its earnings results on Monday, August, 9th. The company reported $2.47 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.54 by $0.07. The firm earned $153.60 million during the quarter, compared to analysts' expectations of $197.34 million.
How has Fulgent Genetics' stock price been impacted by Coronavirus (COVID-19)?
Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FLGT shares have increased by 847.6% and is now trading at $95.33.#N#View which stocks have been most impacted by COVID-19.
What guidance has Fulgent Genetics issued on next quarter's earnings?
Fulgent Genetics updated its third quarter 2021 earnings guidance on Monday, September, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $125 million-$150 million, compared to the consensus revenue estimate of $146.10 million.
Are Robust Financials Driving The Recent Rally In Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Stock?
Fulgent Genetics' (NASDAQ:FLGT) stock is up by a considerable 41% over the past three months. Given the company's...
Why Shares of Fulgent Genetics Are Plunging Today
Shares of coronavirus testing company Fulgent Genetics (NASDAQ: FLGT) are down 16.2% to $91.98 apiece as of 10:30 a.m. EDT. Fulgent derives the overwhelming majority of its revenue from coronavirus testing.
Fulgent Genetics Reports Second Quarter Financial Results
TEMPLE CITY, Calif., August 09, 2021--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "company"), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its second quarter ended June 30, 2021.
Fulgent Genetics Announces Acquisition of CSI Laboratories
TEMPLE CITY, Calif., August 09, 2021--Fulgent Genetics, Inc.
Fulgent Genetics and Helio Health Announce Strategic Partnership to Commercialize Early Cancer Detection Tests
TEMPLE CITY, Calif. & IRVINE, Calif., August 09, 2021--Fulgent Genetics, Inc.
What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?
Fulgent Genetics' (FLGT) Q2 results are likely to reflect growth in areas like adult neurogenetics, hereditary cancer, hereditary cardiovascular genetics, reproductive health and sequencing as a service.
2 Stocks that Could be the Next GME or AMC
Loaded Rifle Investing Think back to early 2020 — a time when r/WallStreetBets was still a dark corner of the internet and the word “Robinhood” conjured images of line-dancing men in a Mel Brooks spoof.
How long are futures trading delayed?
Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle.
How to calculate restricted stock?
To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company's dividend expressed as a percentage of its current stock price.
How to calculate P/E?
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Recently Viewed Tickers
Visit a quote page and your recently viewed tickers will be displayed here.
Fulgent Genetics Inc
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.
